Omada Health, Inc. (OMDA)
| Market Cap | 817.04M -29.6% |
| Revenue (ttm) | 333.04M +43.3% |
| Net Income | 14.03M |
| EPS | 0.23 |
| Shares Out | 62.04M |
| PE Ratio | 58.40 |
| Forward PE | 19.18 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,679,293 |
| Open | 13.99 |
| Previous Close | 14.08 |
| Day's Range | 13.15 - 14.41 |
| 52-Week Range | 10.28 - 25.45 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 26.50 (+101.22%) |
| Earnings Date | Nov 5, 2026 |
About OMDA
Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States. The company offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address musculoskeletal conditions; other support programs for members taking glucagon-like peptide-1 agonists in its cardiometabolic program; and weight management programs, as well as various behavioral health support programs. It also delivers virtual care. The company offers its programs for emplo... [Read more]
Financial Performance
In 2025, Omada Health's revenue was $260.21 million, an increase of 53.24% compared to the previous year's $169.80 million. Losses were -$12.78 million, -72.89% less than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for OMDA stock is "Buy." The 12-month stock price target is $26.5, which is an increase of 101.22% from the latest price.
News
Omada Health Presents AI-Powered Meal Feedback Research and 12-Month GLP-1 Care Track Outcomes at ObesityWeek 2026
Omada's AI-powered Meal Map tool, built to focus on nutrient quality rather than restrictive eating, helped members build meal-tracking habits linked to greater weight loss at week 16. In Omada's GLP-...
Omada Health price target lowered to $25 from $30 at JPMorgan
JPMorgan lowered the firm’s price target on Omada Health (OMDA) to $25 from $30 and keeps an Overweight rating on the shares.
Omada Health price target lowered to $19 from $22 at Wells Fargo
Wells Fargo analyst Stan Berenshteyn lowered the firm’s price target on Omada Health (OMDA) to $19 from $22 and keeps an Equal Weight rating on the shares. The firm notes…
Omada selling season questions linger despite Q3 beat and raise, says Canaccord
Canaccord says Omada Health’s (OMDA) Q3 results were “strong,” topping the firm’s and consensus estimates by “a wide margin across the board,” and notes that FY26 revenue guidance was raised…
Omada Health price target lowered to $22 from $24 at Barclays
Barclays lowered the firm’s price target on Omada Health (OMDA) to $22 from $24 and keeps an Overweight rating on the shares.
Omada Health reports Q3 EPS 10c, consensus 10c
Reports Q3 revenue $91.31M, consensus $85.64M. Total members reached 1.1M, increasing 36% vs. last year, driven by strong enrollment momentum across diabetes and hypertension programs. “Omada Health (...
Omada Health raises FY26 revenue outlook to $344M-$346M from $334M-$340M
Consensus for FY26 revenue is $338.7M. The company raised its full year guidance following strong growth in diabetes and hypertension programs and record member tenure.
Omada Health Earnings Call Transcript: Q3 2026
Q3 revenue grew 34% YoY to a record $91M, with nearly $7M in GAAP net income and record $12M Adjusted EBITDA. FY2026 revenue and Adjusted EBITDA guidance rose, while Q4 revenue and member counts are expected to moderate sequentially.
Omada Health Earnings release: Q3 2026
Omada Health released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Omada Health Slides: Q3 2026
Omada Health has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
Omada Health Quarterly report: Q3 2026
Omada Health has published its Q3 2026 quarterly earnings report on November 5, 2026.
Omada Health Reports Third Quarter 2026 Results
Quarterly Revenue of $91 million and All-Time High Total Members of 1.1 million Revenue Grew 34% and Total Members Increased 36% Year over Year Raises Full Year 2026 Financial Outlook SAN FRANCISCO, N...
Omada Health price target lowered to $24 from $27 at Barclays
Barclays analyst Saket Kalia lowered the firm’s price target on Omada Health (OMDA) to $24 from $27 and keeps an Overweight rating on the shares. The firm expects a modest…
Omada Health to Present Peer-Reviewed Research on Improving Weight Loss and Body Composition During GLP-1 Treatment at World Obesity and Weight Management Congress
SAN FRANCISCO, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, announced it will present research at the World Obesity and Weight Manageme...
Omada Health to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 5, 2026
SAN FRANCISCO, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that it will release its third quarter 2026 results on Thur...
Omada Health price target raised to $27 from $25 at Barclays
Barclays analyst Saket Kalia raised the firm’s price target on Omada Health (OMDA) to $27 from $25 and keeps an Overweight rating on the shares following the investor day. The…
Omada Health Transcript: Investor Day 2026
Omada aims to expand its cardiometabolic care platform by leveraging AI, multi-product offerings, and strong partnerships. Financial guidance was raised, with gross margin targets at 80% and EBITDA at 30%, supported by efficiencies and high retention. GLP-1 solutions, innovation, and engagement drive growth.
Omada Health Slides: FY 2026
Omada Health has posted slides in relation to its FY 2026 quarterly earnings report, which was published on September 10, 2026.
Omada Health presents long-term financial targets at investor day
Omada Health (OMDA) will present its long-term financial targets at the company’s inaugural investor day, being held at the Four Seasons Hotel in New York, New York. Omada is announcing…
Omada Health to Present Updated Long-Term Financial Targets at Inaugural Investor Day
SAN FRANCISCO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit healthcare provider, will present its long-term financial targets at the company's inaug...
Independent Model Estimates Up To $11,142 in Gross Medical Cost Savings Per Member Over Five Years for Omada's GLP-1 Program
SAN FRANCISCO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit healthcare provider, announced a new, independent cost savings model that examined the m...
Omada Health price target raised to $25 from $15 at Baird
Baird analyst Vikram Kesavabhotla raised the firm’s price target on Omada Health (OMDA) to $25 from $15 and keeps a Neutral rating on the shares. The firm updated its model…
Omada Health price target raised to $32 from $27 at Citizens
Citizens analyst Constantine Davides raised the firm’s price target on Omada Health (OMDA) to $32 from $27 and keeps an Outperform rating on the shares. The firm updated its model…
Omada Health price target raised to $30 from $26 at JPMorgan
JPMorgan raised the firm’s price target on Omada Health (OMDA) to $30 from $26 and keeps an Overweight rating on the shares.
Omada Health Transcript: Canaccord Genuity's 46th Annual Growth Conference
The company has evolved from a single-product focus to a broad cardiometabolic suite, achieving record revenue and margin expansion through channel partnerships and operational efficiencies. Its activity-based revenue model and flexible GLP-1 offerings drive growth and cross-selling opportunities.